1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. PDGFR
  4. PDGFR Isoform

PDGFR

 

PDGFR Related Products (59):

Cat. No. Product Name Effect Purity
  • HY-15463
    Imatinib
    Inhibitor 99.95%
    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.
  • HY-50946
    Imatinib Mesylate
    Inhibitor 99.98%
    Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
  • HY-101561
    Avapritinib
    Inhibitor 99.94%
    Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively.
  • HY-10209
    Masitinib
    Inhibitor 99.98%
    Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit).
  • HY-15511
    Tyrphostin A9
    99.87%
    Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission.
  • HY-13263
    CHIR-124
    Inhibitor 98.57%
    CHIR-124 is a potent and selective Chk1 inhibitor with IC50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC50s of 6.6 nM and 5.8 nM.
  • HY-10372
    PP121
    Inhibitor 99.08%
    PP121 is a multi-targeted kinase inhibitor with IC50s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.
  • HY-10202
    Tandutinib
    Inhibitor 99.48%
    Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively.
  • HY-N0366
    Sennoside B
    Inhibitor 99.08%
    Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia).
  • HY-10185
    TG 100572 Hydrochloride
    Inhibitor 99.58%
    TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
  • HY-13904
    Flumatinib
    Inhibitor 99.94%
    Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl.
  • HY-109190
    Seralutinib
    Inhibitor 99.77%
    Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor.
  • HY-10209A
    Masitinib mesylate
    Inhibitor 99.83%
    Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit).
  • HY-10408
    Ki20227
    Inhibitor 99.17%
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β).
  • HY-101957
    AG 1295
    Inhibitor 99.90%
    AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor.
  • HY-109019
    Vorolanib
    Inhibitor 99.14%
    Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor.
  • HY-18622
    PP58
    Inhibitor 99.48%
    PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values.
  • HY-B1016
    Trapidil
    Inhibitor ≥98.0%
    Trapidil is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor.
  • HY-100434
    PD-161570
    Inhibitor 99.04%
    PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM.
  • HY-100349
    SU4312
    Inhibitor 98.19%
    SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312.